Impact of denosumab on bone mass in cancer patients. - Wikidata - wikimedia - TriplyDB

Impact of denosumab on bone mass in cancer patients.

Impact of denosumab on bone mass in cancer patients.

http://www.wikidata.org/entity/Q37000157

about

The neurobiology of skeletal pain Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis.Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab.RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer.

P2860

Q34402192-5CD832F7-DB0F-4C90-93EA-7201B7657CBD Q34545263-3AEAB31C-C45C-410B-AE45-272FD67011D8 Q42508259-C5753030-21E5-41ED-8F8D-DE4F699CB2CE Q47140509-59C31781-A690-477E-B810-801E54B8ACDC

P2860

Impact of denosumab on bone mass in cancer patients.

http://www.wikidata.org/entity/Q37000157

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 04 July 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Impact of denosumab on bone mass in cancer patients.

@en

Impact of denosumab on bone mass in cancer patients.

@nl

type

label

Impact of denosumab on bone mass in cancer patients.

@en

Impact of denosumab on bone mass in cancer patients.

@nl

prefLabel

Impact of denosumab on bone mass in cancer patients.

@en

Impact of denosumab on bone mass in cancer patients.

@nl

P1433

Q37000157-AD0A4334-2C26-43BC-85D2-1901B0F7096F

P1476

Q37000157-1F794987-B937-49D0-971C-AB3AF66D0151

P2093

Q37000157-91337D5D-A8E9-44E4-A757-6CF0C06840E7

Q37000157-C3944F45-F3F5-4650-86CB-4E74867302F0

P2860

Q37000157-00A6AA6A-32A6-4AC1-9776-323958E4344C

Q37000157-01A2DD58-C7DD-4DEA-B69C-72D7C860EF0A

Q37000157-0507CAA5-3680-4869-8A49-CA0BBD309DCF

Q37000157-068846B0-B6EC-484A-B501-CE2A7502344A

Q37000157-08779F2C-92E6-4DAB-A528-58A34CB02C0B

Q37000157-0AB66269-E096-4ABF-98CA-E815AD78A728

Q37000157-13AD1597-A896-4C23-B83B-08BF44726C37

Q37000157-15BC8E8A-8870-493A-9544-1A348A05DFF7

Q37000157-1A429584-86B5-4E87-A69A-A38238461CFF

Q37000157-1F81C2E5-4BCD-4A8D-94D1-A70BDAF63C91

P304

Q37000157-F7ACBC60-5A1F-48C0-B326-1037C3FC929A

P31

Q37000157-6DF36F20-826D-4C94-8EBE-641CF1BC9133

P356

Q37000157-B91A8C5D-2BFC-4096-82E6-2D1284D9682C

P407

Q37000157-99CA4005-9FE5-48A8-9B26-CDEDE6ED991E

P478

Q37000157-404400E9-855E-4C7E-B87B-6D68CDDB3062

P577

Q37000157-DB675500-E4CD-4724-8875-80C071AC7E51

P698

Q37000157-B09A1832-6502-4611-852B-4B5FA5BACE16

P932

Q37000157-728C4503-68C3-44DC-ADD0-8CCDF512CF73

P356

P1433

Clinical Pharmacology: Advances and Applications

P1476

Impact of denosumab on bone mass in cancer patients.

@en

P2093

Alison T Stopeck

http://www.w3.org/2001/XMLSchema#string

Ursa Brown-Glaberman

http://www.w3.org/2001/XMLSchema#string

P2860

Bisphosphonates and other bone agents for breast cancer

Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis

Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis

Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials

RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis

Elimination mechanisms of therapeutic monoclonal antibodies

Abnormalities in serum osteocalcin values in children receiving chemotherapy including ifosfamide

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

P304

117-129

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CPAA.S30330

http://www.w3.org/2001/XMLSchema#string

P407

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23861604

http://www.w3.org/2001/XMLSchema#string

P932

3707483

http://www.w3.org/2001/XMLSchema#string